Corporate health programmes produce plenty of data. Enrolment rates, session completion, app downloads, satisfaction scores. The harder number, whether the health of the workforce actually changed, is usually missing.
That gap matters more than it might seem.
What ROI actually requires
The Institute for Public Policy Research estimated that UK employers lost £103 billion to presenteeism in 2023. Employees showing up while managing uncontrolled chronic conditions, operating below capacity. This cost doesn't appear in absence data, doesn't show up in EAP utilisation, and doesn't register in a headcount report. It accumulates quietly in output, decision quality, and over time, retention.
A programme that reduces absenteeism by one day per employee looks good in a board presentation. A programme that improves the clinical health of a chronically ill population does something more durable. Connecting those two things requires a different measurement approach than most programmes are built for.
ROI on a chronic disease programme has three components: clinical improvement in the participant population, productivity recovered, and downstream cost reduction. Each requires different data, tracked at different timepoints.
Clinical improvement
Weight, HbA1c, blood pressure, and waist circumference are the outcomes that determine whether a programme is doing anything medically meaningful.
NHS/Liva data from the Type 2 Diabetes Path to Remission Programme shows 74% of patients with Type 2 diabetes achieved normal HbA1c within 6 months. Hesseldal et al. found an average waist circumference reduction of 9.9cm at 12 months. These numbers are the clinical signal. Without them, you're measuring activity.
For employers, this means requiring clinical outcome data as a condition of any programme renewal conversation. Providers who can't produce it haven't been tracking it.
Productivity recovered
Legal and General's research puts the presenteeism-to-absenteeism ratio at 3:1. For every £1 lost to absence, £3.50 is lost to impaired performance at work. A 2024 analysis in Nature found that 78% of obesity-related productivity costs are invisible to standard HR reporting.
Where data sharing agreements allow, clinical improvement data can be linked to workforce performance data over time. Absence rates in the participant group versus a comparable non-participant cohort. Self-reported productivity before and after. The connection is harder to establish than clinical markers, but it's the link that holds up with a finance team.
This requires setting up the data infrastructure before the programme starts. Most organisations try to build the case retrospectively. By then, the baseline is gone.
Downstream cost reduction
For employers with group insurance or self-funded health benefits, clinical improvement eventually translates into reduced claims. The European Commission has estimated that every €1 invested in chronic disease prevention returns €14 in reduced treatment costs and productivity gains.
The timing is the complication. Prevention returns don't arrive in year 1. They arrive in year 3 to year 5, as progression from prediabetes to Type 2 diabetes slows, as cardiovascular events are deferred, as obesity-related conditions are managed rather than reactive. A measurement framework that only looks at year 1 data will underestimate the programme's value significantly.
ROI measurement for chronic disease needs a 3 to 5 year reporting horizon.
A practical measurement framework
Three questions, asked at consistent timepoints, give a workable picture.
At 3 months: is engagement holding? Active use by month 3 is a leading indicator of long-term outcomes. Programmes that lose participants in the first 90 days rarely recover them.
At 6 months: are clinical markers improving? If weight, HbA1c, blood pressure, and waist circumference aren't moving, the programme design needs reviewing before month 12.
At 12 months: what's changed in the workforce? Participant absence rates compared against a non-participant cohort. Self-reported productivity. Any available claims data. And, importantly, the clinical trend lines: are the improvements from month 6 holding?
The framework is straightforward. It requires deciding, at the start, what will be measured, and working with a programme provider that can supply the clinical data to support it.
How we approach this
Our clinician portal gives programme leads real-time visibility into cohort-level outcomes across the participant group: weight, HbA1c, activity levels, and self-reported wellbeing. Reporting connects participation with measurable health improvement rather than enrolment figures.
For corporate clients, this means the renewal conversation can be grounded in outcome data. Liva is a NICE-approved provider for digital specialist weight management services, with an RCT showing a 9.9cm average waist circumference reduction at 12 months (Hesseldal et al., J Med Internet Res 2022;24(9):e39741) and NHS/Liva data showing 74% of T2D patients achieving normal HbA1c within 6 months on the T2DR programme.
The measurement infrastructure comes with the programme.
A chronic disease programme with clinical outcome data, a productivity linkage, and a 5-year cost horizon is a business case. One running on enrolment figures alone is a wellbeing benefit with an unclear return.
The difference is in what gets measured, and whether that decision was made before the programme launched.
